Building Decision Points Into Research’s Slipperiest Slopes
By John H. Evans, Craig Callender, Neal K. Devaraj, Farren J. Isaacs, and Gregory E. Kaebnick,
Issues in Science and Technology
| 07. 04. 2025
The controversy around a ban on “mirror life” should lead to a more nuanced public conversation about how to manage the benefits and risks of precursor biotechnologies.
About five years ago, the five of us formed a discussion group to investigate the ethics of working with the building blocks of mirror life—biomolecules that are essentially mirror images of their natural counterparts. We knew that less-novel research within the broader field of synthetic biology has been the subject of extensive social and ethical debates, so we wanted to be proactive about a technology we consider even more novel. Two of us (Devaraj and Isaacs) are synthetic biologists who focus on lipids, nucleic acids, and proteins. The rest are a philosopher of science (Callender), a social ethicist of biotechnology (Evans), and a bioethicist (Kaebnick). We met roughly quarterly to discuss what was happening in our labs, as well as the possible futures of such technology.
Last year, Devaraj and Isaacs were invited into a second group, a large consortium of dozens of synthetic biologists and research leaders preparing a statement on...
Related Articles
By Abby McCloskey, The Dallas Morning News | 10.10.2025
We Texans like to do things our way — leave some hide on the fence rather than stay corralled, as goes a line in Wallace O. Chariton’s Texas dictionary This Dog’ll Hunt. Lately, I’ve been wondering what this ethos...
By Jay S. Kaufman, Los Angeles Review of Books | 09.27.2025
This is the 10th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. The series is organized by Osagie K. Obasogie in...
By Julia Black, MIT Technology Review | 10.16.2025
Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...